Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1202

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1202
---
 Davis is qualified to serve on
the board of directors because of his extensive experience within the life sciences industry, including as a founder and managing
partner of a special opportunities investment firm.

Ezra
Friedberg has served on our board of directors since May 2021, bringing over 30 years of investment experience across
public and private markets. Since co-founding Multiplier Capital in 2011, a private credit fund specializing in sponsor-backed
growth companies, he has acted as General Partner and a member of the fund’s investment committee. A seasoned investor, Mr. Friedberg
has a strong focus on the biotechnology sector, including his tenure on the board of Humanigen (Nasdaq: HGEN), a clinical-stage
biopharmaceutical company developing monoclonal antibodies. His broader portfolio spans private equity, venture capital, and real
estate investments.  In addition to his work with Multiplier Capital, Mr. Friedberg manages diverse investments and businesses
through Liberty Peak Capital, Key Recovery Group, and related entities. A graduate of Johns Hopkins University, he is also deeply
committed to civic engagement, having founded and actively served on the boards of several community organizations, including
a nonprofit mentoring agency. His extensive investment expertise and understanding of our industry were key factors in his selection
to our board of directors.

Dr.
Richard Malamut has served as a member of our board of directors since January 2023. Dr. Malamut is currently Chief Medical
Officer at MedinCell Inc. He was most recently Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals
from April 2019 to May 2022 and has also served as Chief Medical Officer for Braeburn Pharmaceuticals, Inc. from 2018 to 2019
where he was responsible for the company’s medical affairs, non-clinical and clinical development, clinical operations,
research and development quality assurance, and pharmacovigilance functions. Prior to that, Dr. Malamut had similar responsibilities
as Chief Medical Officer at Avanir Pharmaceuticals from 2016 to 2018 and was Senior Vice President of Global Clinical Development
at Teva Pharmaceutical Industries Ltd from 2013 to 2016 where he was responsible for Pain, Neuropsychiatry, Oncology, and New
Therapeutic Entities. His experience also includes roles of increasing responsibility focusing on early clinical development and
translational medicine in Neurology, Psychiatry and Analgesia at Bristol-Myers Squib